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Previously, we have reported linkage of markers from chromosome 1q22 to schizophrenia, a ﬁnding supported by
several independent studies. We have now examined the region of strongest linkage for evidence of linkage dis-
equilibrium (LD) in a sample of 24 Canadian familial-schizophrenia pedigrees. Analysis of 14 microsatellites and
15 single-nucleotide polymorphisms (SNPs) from the 5.4-Mb region between D1S1653 and D1S1677 produced
signiﬁcant evidence (nominal ) of LD between schizophrenia and 2 microsatellites and 6 SNPs. All of theP ! .05
markers exhibiting signiﬁcant LD to schizophrenia fall within the genomic extent of the gene for carboxyl-terminal
PDZ ligand of neuronal nitric oxide synthase (CAPON), making it a prime positional candidate for the schizo-
phrenia-susceptibility locus on 1q22, although initial mutation analysis of this gene has not identiﬁed any schizo-
phrenia-associated changes within exons. Consistent with several recently identiﬁed candidate genes for schizo-
phrenia, CAPON is involved in signal transduction in the NMDA receptor system, highlighting the potential
importance of this pathway in the etiology of schizophrenia.
Schizophrenia (SCZD [MIM 181500]) is a serious neu-
ropsychiatric illness estimated to affect ∼1% of the gen-
eral population. Family, twin, and adoption studies have
demonstrated that schizophrenia is predominantly a ge-
netic disorder with a high heritability (reviewed in
McGufﬁn et al. 1994). Multiple genetic and nongenetic
factors are likely to be involved (Bassett et al. 2001b).
As part of a genomewide search for loci contributing to
risk for schizophrenia, we previously reported linkage
to chromosome 1q21-22 (SCZD9 [MIM 604906]) in a
group of 22 medium-sized Canadian families, selected
for study because multiple relatives were clinically di-
agnosed with schizophrenia or with schizoaffective dis-
order (Brzustowicz et al. 2000). Parametric multipoint
linkage analysis, under a recessive model of inheritance
and using a narrow deﬁnition of illness (schizophrenia
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and schizoaffective disorder), produced a maximum het-
erogeneity LOD score of 6.50 between the markers
D1S1653 and D1S1679. Simulation studies conﬁrmed
the genomewide signiﬁcance of this LOD score, even
when accounting for multiple tests, with .P ! .0002
Most recently, we have reported the results of ﬁne link-
age mapping of this 1q21-22 region in the same sample
of individuals, narrowing the region most likely to har-
bor this susceptibility locus to ∼1 Mb between APOA2
and D1S2675 (Brzustowicz et al. 2002). Again, results
showed a maximum multipoint heterogeneity LOD
score of 6.50, under the same recessive-narrow genetic
and diagnostic model (Brzustowicz et al. 2002). Here,
we report the results of linkage disequilibrium (LD) anal-
ysis of this region.
The subjects for this study included the individuals
that were used for our previous genome scan and ﬁne
linkage mapping studies (Brzustowicz et al. 2000, 2002).
Two new families ( participating subjects) andnp 17
additional members of the previously studied families
( ) were also included. Written informed consentnp 25
was obtained from all subjects, after an explanation of
possible consequences. Protocols were approved by the
institutional review boards of Rutgers University, Uni-
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versity of Toronto, and by the Centre for Addiction and
Mental Health. The ascertainment procedures and com-
position of the original sample have been previously de-
scribed in greater detail (Bassett et al. 1993; Bassett and
Honer 1994; Brzustowicz et al. 2000). The current sam-
ple consisted of 24 Canadian families of Celtic (np
) or German ( ) descent, recruited for study be-23 np 1
cause schizophrenic illness appeared to be segregating in
a unilineal (one side of the family) autosomal–dominant-
like manner.
For this study, we used a narrow deﬁnition of schizo-
phrenia; only individuals with schizophrenia and chronic
schizoaffective disorder were coded as affected. Direct
interviews were conducted, using the Structured Clinical
Interview for DSM-III-R (SCID-I) for major disorders
and the SCID-II for personality disorders. The inter-
views, collateral information, and medical records were
used to make consensus diagnoses for 319 subjects based
on DSM-III-R criteria. For 11 additional subjects—2
alive, but unavailable for full phenotypic assessment,
and 9 deceased—only medical records and collateral in-
formation were reviewed, through the consensus diag-
nosis procedure. Details of the diagnostic and ascertain-
ment methods have been described elsewhere (Bassett et
al. 1993; Bassett and Honer 1994). Consensus diagnosis
(by E.W.C.C. and A.S.B.) of narrow-deﬁnition schizo-
phrenia was not obtained for four subjects, possiblywith
affective psychotic illness, who were directly assessed,
or for the two living subjects, who were not directly
assessed; therefore, these individuals were coded as “di-
agnosis unknown.” Three additional subjects, each from
a separate family, were coded as diagnosis unknown,
because mental retardation complicated their assess-
ment. Of the nine deceased subjects, four were coded as
unknown, because conclusive diagnostic elements could
not be obtained, and ﬁve were determined to be affected.
In total, 85 subjects, or an average of 3.5 subjects per
family, were considered affected with narrowly deﬁned
schizophrenia. There were 13 subjects with phenotypic
data who were coded as unknown and 232 subjects con-
sidered unaffected, including 40 individuals with the
schizophrenia spectrum diagnoses of nonaffective psy-
chotic disorder, schizotypal personality disorder, or par-
anoid personality disorder. DNA samples were available
on 11 additional subjects without phenotypic assess-
ments, who were coded as unknown. DNA was un-
available on the nine deceased subjects. DNA was ex-
tracted from blood samples or lymphoblastoid cell lines
using the GenePure system (Gentra Systems). Overall,
330 subjects were phenotypically evaluated and 332 sub-
jects had DNA samples available for this study.
Microsatellite marker genotypes generated for our
ﬁne-mapping study, described elsewhere (Brzustowicz et
al. 2002), were used for this study. SNP genotypes were
generated by a primer-extension strategy (Pyrosequenc-
ing) and were typed as simplex assays using the auto-
mated PSQ HS96A platform (Ronaghi et al. 1998; Ah-
madian et al. 2000). SNPs were identiﬁed either from
dbSNP or by semiautomated ﬂuorescent sequencing
(Beckman CEQ 8000), using DNA from 16 members of
these families. PCR primers surrounding the SNPs were
designed using Primer3 (Whitehead Institute), and the
sequencing primer used for the Pyrosequencing assay
was designed using the Pyrosequencing SNP Primer De-
sign Software v 1.0. Web Supplement. Table A1 (ap-
pendix A [online only]) lists the primers used for the
Pyrosequencing assays. PCR reactions contained 40 ng
of template DNA, 0.5 U Taq polymerase, 0.03 mM of
each primer, 0.1 mMof dNTP, 3.0mMofMgCl2, 50mM
of KCl, 10mM of Tris—HCl (pH 9.0), and 0.1% Triton
X-100 in a 20 ml volume. A touchdown ampliﬁcation
program was used. After 8 min at 95C, 15 cycles were
done at 94C for 30 s, annealing for 20 s, and at 72C
for 20 s, with the annealing temperature starting at 60C
and decreasing by 0.5C for each cycle. This was fol-
lowed by 35 cycles at 94C for 20 s, at 52C for 20 s,
at 72C for 30 s, and then a ﬁnal extension step at 72C
for 15 min.
Genotypes were checked for likely errors by use of
the mistyping analysis of SIMWALK2 v2.82 (Sobel and
Lange 1996; Sobel et al. 2001). Because different starting
conditions can generate different results when SIM-
WALK2 is used, mistyping analyses were conducted at
least four consecutive times, with varying starting con-
ditions, using all markers simultaneously. Genotypes
identiﬁed with a probability of mistyping 0.25 were
regenotyped. The repeated microsatellite genotypes still
having a probability of mistyping0.25 were set to zero
for further analyses, whereas ﬂagged SNP genotypes
were further veriﬁed by direct sequencing. Ultimately,
only three SNP genotypes (0.06%) identiﬁed as potential
errors could not be resolved; these all occurred in un-
affected individuals, and the omission of those SNP ge-
notypes from the study did not change the results of the
LD analysis. Overall, 99.6% of all SNP genotypes ini-
tially attempted were available for further analysis, with
100% of SNP genotypes available for affected individ-
uals. Allele frequencies (table 1) were calculated using
FBAT v1.4.2 (Laird et al. 2000; Horvath et al. 2001).
SIMWALK2 v2.82 was also used to generate haplo-
types for analysis of marker-to-marker LD. Ten SIM-
WALK2 runs were performed on the data after error
checking, with a variety of initial analysis parameters,
to identify the most likely haplotypes. Genotypes from
all 15 SNPs, as well as from the seven microsatel-
lite markers APOA2, B195G14.ttg1, B366H14.tcta1,
B366H14.ca1, D1S2675, D1S1679, and D1S2768, were
used simultaneously for haplotype generation. Marker
order was set according to build 34 of the human ge-
nome assembly (UCSC). To identify and remove any
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Table 1
LD between Schizophrenia and Markers within CAPON
EVIDENCE OF LD, GIVEN
LINKAGE
SNP MARKERSa
DISTANCEb
(bp) LOCATION ALLELESc ALLELE FREQUENCYd Nominal Pe Empiric Pf
ss16342088 0 5′ A/G .31 .44 .49
336H14-tcta1 3,997 Intron 1 (8) (.70) .74 …
rs1572495 61,445 Intron 1 C/T .12 .018 .021
rs1538018 92,625 Intron 2 G/T .30 .032 .047
rs945713 97,810 Intron 2 A/G .41 .011 .016
rs1415263 128,187 Intron 2 C/T .38 .0011 .0016
336H14-ca1 131,530 Intron 2 (12) (.78) .044 …
rs4306106 134,138 Intron 2 C/T .14 .050 .079
rs3934467 144,821 Intron 2 C/T .18 .12 .17
rs3924139 154,256 Intron 2 A/G .30 .059 .068
D1S2675 172,105 Intron 2 (7) (.65) .036 …
rs4145621 180,832 Intron 2 A/G .41 .0017 .0016
ss16342089 219,177 Intron 2 G/C .22 .087 .10
rs2661818 226,958 Intron 4 C/G .43 .0022 .0032
rs1508263 241,653 Intron 4 A/G .45 .53 .55
rs3751284 275,879 Exon 6 G/A .30 .84 .84
rs7521206 293,071 Intron 8 C/G .43 .54 .58
rs348624 297,400 Exon 9 G/A .05 .11 .15
D1S1679 323,908 3′ (9) (.83) .92 …
a Markers are listed from centromeric to telomeric; microsatellite markers are in italics.
b Distance is measured from the ﬁrst marker, ss16342088, on the basis of NCBI build 34 assembly.
c The more common allele is listed ﬁrst (for microsatellites, the number of observed alleles is in parentheses).
d Frequency of the rare allele is listed (for microsatellites, the heterozygosity is listed in parentheses).
e Nominal P values were calculated by PSEUDOMARKER.
f Empiric P values meeting studywide signiﬁcance level of P!.05 are in boldface italics.
haplotypes with one or more markers that could not be
deﬁnitively phased, the resulting haplotypes were com-
pared across runs. Thirteen founder haplotypes were re-
moved because they could not be fully phased, and 178
fully phased founder haplotypes were deﬁned in this
sample. Founder haplotypes were then collected into in-
put ﬁles for GOLD to assess marker-to-marker LD (Abe-
casis and Cookson 2000).
In testing for evidence of LD to schizophrenia, we
wanted to use an analysis method that could take full
advantage of the extended pedigree structure of the fam-
ilies in our study, but also one that would clearly separate
the evidence for LD from the strong evidence for linkage
in this sample. On this basis, we elected to use the pro-
gram PSEUDOMARKER v0.9.7 to conduct analyses of
LD (Goring and Terwilliger 2000). PSEUDOMARKER,
unlike many popular TDT-based programs, explicitly
separates the evidence for linkage and LD in families
with multiple affected individuals. Simulation studies
also indicate that PSEUDOMARKER has greater power
than FBAT (Laird et al. 2000; Horvath et al. 2001) and
PDT (Martin et al. 2000; Martin et al. 2001) to detect
LD in this sample (Brzustowicz et al. 2003). For each
marker, PSEUDOMARKER provides separate evalua-
tions for evidence of linkage, of LD given linkage, of LD
given no linkage, of linkage given LD, and for a joint
test of linkage and LD. On the basis of the most favored
model from our prior linkage results for the 1q22 locus,
analyses were conducted using a recessive pseudomarker
model and a narrow deﬁnition of “affected” (schizo-
phrenia or schizoaffective disorder) (Brzustowicz et al.
2000).
Simulation studies were conducted to assess the sig-
niﬁcance of our ﬁndings. The analysis of multiple mark-
ers for LD raises the possibility of false positive ﬁndings
due to multiple testing. However, as marker-to-marker
disequilibrium is likely to exist over small physical dis-
tances, these tests are not independent, and a Bonferroni
correction for multiple testing would be overly conser-
vative. In addition, we were concerned about the pos-
sibility that the strong linkage signal in this sample could
bias the analysis of LD. Our goal was to provide an
appropriate correction of type I error in the evidence of
LD, under the situation of strong linkage and marker-
to-marker LD. We therefore devised a simulation strat-
egy to address this issue. First, the general segregation
of haplotypes within the pedigrees was deﬁned using
SIMWALK2 with the haplotype label option. The pop-
ulation of fully phased founder haplotypes was then
shufﬂed and randomly reassigned to the segregating hap-
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Figure 1 Map of genomic structure of CAPON with genetic markers indicated. Asterisks (*) indicate SNPs that reach studywide empirical
signiﬁcance for LD at the level.P ! .05
lotype labels. On average, this procedure is expected to
preserve the marker-to-marker LD (since the original real
founder haplotypes are used) and to preserve themarker-
to-disease linkage signal of the original sample (since the
same pattern of allele sharing among relatives within
each pedigree is maintained), but it also should generate
a random marker-to-disease LD signal. We analyzed
2,500 replicates. Owing to the predominance of SNP
markers within the region of interest and to the com-
putational burden of conducting PSEUDOMARKER
analysis with highly polymorphic microsatellite markers
(since computation time increases exponentially with the
number of alleles), simulations were restricted to the set
of 15 SNPs. Each simulated replicate was analyzed by
the same analysis method as the real data (recessive pseu-
domarker analysis with a narrow disease deﬁnition), and
a distribution of results was assembled to allow empiric
evaluation of the results of the real-data analysis.
Evidence of LD between schizophrenia susceptibility
and markers from chromosome 1q22 was assessed in
two stages. For the ﬁrst stage of analysis, the 14 micro-
satellites from D1S1653 to D1S1677, that were previ-
ously used for the ﬁne genetic linkage mapping of this
region (Brzustowicz et al. 2002), were screened for LD,
using PSEUDOMARKER, under a recessive pseudo-
marker model. Consistent with prior results, all these
markers produce signiﬁcant evidence (nominal )P ! .05
of linkage to schizophrenia, but only two—336H14-
ca1 (nominal ) and D1S2675 (nominalPp .044 Pp
)—produced signiﬁcant evidence (nominal ).036 P ! .05
of LD to schizophrenia, given linkage. As both of these
markers were located within the genomic extent of CA-
PON, or carboxyl-terminal PDZ ligand of neuronal ni-
tric oxide synthase, additional markers within this gene
were selected for further study.
For the second stage of analysis, 15 SNPs from CA-
PON were evaluated for LD (ﬁg. 1). Twelve of these
were from intronic sequences, one 5′ to the gene
(ss16342088), one from exon 6 (rs3751284), and one
from exon 9 (rs348624). SNPs rs3751284 and rs348624
represent the only SNPs in the CAPON coding sequence
that were observed during resequencing of 16 individ-
uals from our linkage sample or that are listed in dbSNP,
build 118. Both of these SNPs represent synonymous
substitutions. Marker-to-marker LD was calculated for
all marker pairs, with signiﬁcant pairwise LD detected
through much of the region (ﬁg. 2).
Results of LD analysis of markers from CAPON are
presented in table 1. Of the 15 SNPs from CAPON, 6
exhibited signiﬁcant LD to schizophrenia (nominal P !
). We conducted simulation studies to determine em-.05
piric P values for these results, both for each marker
individually and for the entire set of SNP markers. Em-
piric P values for individual markers indicated that, for
this collection of pedigrees and for this pattern of hap-
lotype segregation, the nominal P values produced by
PSEUDOMARKER were slightly anticonservative (table
1), although results for all six SNPs remained signiﬁcant.
For the full set of 15 SNPs used in this set of pedigrees,
simulations indicated that a nominal P value of !.0025
was required to reach studywide empirical signiﬁcance
at the level.Markers rs1415263, rs4145621, andP ! .05
rs2661818 attained this level of signiﬁcance, with stu-
dywide empirical P values of .019, .036, and .045, re-
spectively. Not surprisingly, these three markers exhibit
signiﬁcant marker-to-marker LD (ﬁg. 2). We also used
simulation results to calculate the overall probability of
observing, by chance, 6 of 15 SNPs showing nominally
signiﬁcant LD to schizophrenia, given the existing pat-
tern of marker-to-marker LD. An empiric P value of .015
was obtained.
Although powerful for linkage analysis, this sample
of 24 independent pedigrees would not be expected to
have much power to detect LD. Overall, a total of 178
founder haplotypes could be reconstructed for the region
investigated, with 90 of these observed to be transmitted
to individuals with schizophrenia. Thus, for purposes of
LD analysis, this set of 330 subjects would be expected
to behave, at best, like a collection of 45 trios, a modest-
size sample for a complex disease-association study. This
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Figure 2 LD (D′) between pairs of SNP markers. Pairs with signiﬁcant evidence ( ) of LD are shaded.P ! .05
makes the detection of signiﬁcant LD in this sample all
the more striking.
Our evidence for LD is centered within the CAPON
gene. The only previous study of LD involving this re-
gion investigated six microsatellite markers spanning 39
cM from 1p21.1-q23.3 in 80 Spanish nuclear families,
and the authors reported signiﬁcant LD to schizophrenia
only for D1S1679 (Rosa et al. 2002), which is located
within 25 kb of the 3′ end of CAPON. The next nearest
markers tested were D1S1653 and D1S1677, whichmap
3.8 Mb 5′ and 1.2 Mb 3′ to CAPON, respectively. Link-
age studies also support a 1q22 positional candidate for
schizophrenia. Several independent studies, including
our own, have shown strong or suggestive linkage to
this region (Shaw et al. 1998; Brzustowicz et al. 2000,
2002; Gurling et al. 2001; Hwu et al. 2003). A large
meta-analysis of genome scans also supports a schizo-
phrenia susceptibility locus in the 1q region (Lewis et
al. 2003). It is important to note that, previously, we
found that an estimated 75% of these families were
linked to 1q22 and also that there was signiﬁcant evi-
dence for linkage to 13q32 in an estimated 65% of fam-
ilies (Brzustowicz et al. 2000), indicating that several
schizophrenia susceptibility genes, including CAPON,
may be active in the same sample.
The expression proﬁle of CAPON further supports
this gene as an appealing candidate for schizophrenia
susceptibility. Human transcripts have been isolated
from the brain and testes of adults and infants (UniGene
database, NCBI). Rat studies reveal expression in the
adult brain, but not in the adrenal, bladder, heart, kid-
ney, lung, or skeletal muscle; the highest expression was
in the cerebral cortex and medulla oblongata (Jaffrey et
al. 1998). Currently, nothing is known about the fetal
expression pattern of CAPON. However, CAPON is
known to participate in neuronal signal transduction
and other pathways that are essential for both neuronal
proliferation and neuronal differentiation in develop-
ment and for synaptic plasticity throughout life (Hata
and Takai 1999; Boehning and Snyder 2003).
CAPON primarily functions as an adaptor protein
targeting neuronal nitric oxide synthase (nNOS). The C-
terminal amino acids of CAPON bind to the PDZ do-
main of the neuronal—but not the other—forms of
NOS, and CAPON and nNOS are colocalized in rat
brains (Jaffrey et al. 1998). CAPON competes with
PSD95 for binding to nNOS. PSD95 is a postsynaptic
density scaffolding protein that binds to both nNOS and
NMDA receptor subunits in neurons, thereby allowing
activation of nNOS by Ca inﬂux through the NMDA
receptor. This produces NMDA receptor-mediated NO
release into the synaptic structures. CAPON, by com-
petitively binding to nNOS, disrupts this coupling and,
thus, inhibits this local NO release (Jaffrey et al. 1998).
This places CAPON at the scene of NMDA glutamate
neurotransmission, long proposed to be involved in
schizophrenia. Abnormal expression of PSD95 and of
related post-synaptic density proteins has also implica-
ted NMDA receptor-associated intracellular pathways
and signal-transduction abnormalities in schizophrenia
(Clinton et al. 2003).
CAPON also targets nNOS to Dexras1 (Fang et al.
2000), thereby facilitating the NO-dependent activation
of this small G-protein (Jaffrey et al. 2002b; Boehning
and Snyder 2003), which is involved in modulating sig-
nal transduction (Graham et al. 2002). Recently, the N-
terminus of CAPON has also been found to interact with
synapsins I, II, and III through a phosphotyrosine-bind-
ing domain, thereby changing the subcellular localiza-
tion of nNOS (Jaffrey et al. 2002a). Synapsins are a
family of phosphoproteins involved in synaptogenesis
and in regulating neurotransmitter release (Ferreira and
Rapoport 2002).
CAPON has not previously been proposed as a can-
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didate gene for schizophrenia. The genetic evidence, ex-
pression pattern, and known functions of this gene,
however, are consistent with prevailing models of schizo-
phrenia pathogenesis, including anomalous neurodev-
elopment (Bassett et al. 2001a) and abnormal synaptic
connectivity (Harrison 1999). Two recent reviews of the
most plausible candidate susceptibility genes for schizo-
phrenia (Harrison and Owen 2003; Sawa and Snyder
2003) propose that most or all are involved in schizo-
phrenia susceptibility through interlinked processes in
glutamatergic synapses, particularly those processes in-
volving NMDA receptors. CAPON’s role in mediating
NMDA receptor-associated signaling would be consis-
tent with this model of schizophrenia pathogenesis. In
addition, the speciﬁc binding of CAPON to nNOS im-
plicates NO, which can have both neuroprotective and
neurotoxic functions. The NO system is directly in-
volved in mediating neuronal response to hypoxia
(Boehning and Snyder 2003) and could ﬁt an integrated
model, including nongenetic factors such as in utero hy-
poxia (Zornberg et al. 2000) and childhood head injury
(AbdelMalik et al. 2003).
Screening of the coding region of CAPON in in-
dividuals from our linkage sample has failed to iden-
tify any mutations that would be predicted to be as-
sociated with altered protein function. This is
consistent with current results for other candidate
genes for schizophrenia (Harrison and Owen 2003).
Given the possibility of trinucleotide repeat expan-
sions in schizophrenia (Bassett and Husted 1997;
Margolis et al. 1999), we examined a small imperfect
CAG repeat within exon 7 ([CAG]2[TCT]2[CAG]6) cod-
ing for polyglutamine with interspersed leucines, for ev-
idence of expansion. We found no evidence of instability
at that site.
CAPON has a large, nearly 300-kb, genomic extent,
only 1.5 kb of which represents coding sequence. There-
fore, there are many potential sites for regulatory se-
quences that could be disrupted and that could lead to
altered protein expression. The markers that exhibit em-
pirically signiﬁcant evidence of LD to schizophrenia span
99 kb and deﬁne a region that includes most of the very
large (133-kb) intron 2 of CAPON. The existence of an
additional gene or genes within this intron cannot be
excluded, providing the possibility of other positional
candidates within the region of LD.
There are now two reports of signiﬁcant LD between
schizophrenia and markers in the CAPON region: this
sample and that of Rosa et al. (2002). It will be very
interesting to see if this association can be detected in
other schizophrenia samples.
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